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Propofol is a widely used intravenous anaesthetic agent. Soon after its introduction into the market, 
propofol-related postoperative infections were reported. It was determined that the emulsion supports 
growth and manufacturers provided strict aseptic guidelines with regards to propofol usage, but it has 
been shown that clinicians in South Africa do not adhere to these guidelines.  
The primary objective of our observational study was to determine the prevalence of contamination of 
syringes containing propofol (Fresenius’ Propoven® 1%, Fresenius Kabi, Sweden) in the Tygerberg 
Hospital Theatre Complex. Samples of syringes containing propofol were collected from various 
randomised operating theatres over a period of 15 days and specimens cultured and tested for growth of 
organisms. 
The secondary objective was to differentiate between contamination occurring in emergency and 
elective surgery operating theatres and investigate the difference in propofol contamination when used 
by junior versus more senior anaesthetists.  
We demonstrated an unacceptably high propofol contamination prevalence of 41.8% (95% CI: 32.5%, 
51.6%). Coagulase negative staphylococcus (CONS) was the most prevalent organism. Overall, 58.18% 
of samples demonstrated no growth after 2 days. Regarding our secondary objective, there was no 
statistically significant difference regarding the prevalence of propofol contamination of samples taken 
from the emergency and elective operating theatres (p = 0.95; risk ratio 1.02; 95% CI: 0.55; 1.89). 
Propofol syringes handled by senior versus junior anaesthetists revealed a similar result (p = 0.65; risk 
ratio 0.90; 95% CI: 0.58; 1.41). 
CONS are often contaminants and the bulk of organisms we cultured are non-pathogenic in healthy 
hosts but can be lethal in immunocompromised patients. Presence of commensals is also a warning that 
any other pathogens (including viruses) that may be present on the anaesthetist’s hands or in the 
environment may also contaminate the propofol.  
The presence of human commensals as well as environmental organisms in the propofol syringes are 





2. OPSOMMING  
Propofol word tans algemeen as intraveneuse narkosemiddel gebruik. Propofol verwante postoperatiewe 
infeksies is egter gou nadat die middel bekendgestel is gerapporteer. Organismes kan groei in die 
emulsie en die vervaardigers het streng aseptiese riglyne vir die gebruik van propofol daargestel. Dit 
blyk egter dat praktisyns in Suid-Afrika nie die riglyne volg nie.   
Die primêre doel van ons beskrywende studie was om die prevalensie van kontaminasie van spuite met 
propofol (Fresenius Propoven® 1%, Fresenius Kabi, Swede) in die Tygerberg Hospitaal Teater 
kompleks te bepaal. Monsters van spuite met propofol is versamel van verskeie gerandomiseerde 
operasieteaters oor ‘n periode van 15 dae. Die monsters is gekweek en evalueer vir die groei van 
organismes.  
Die sekondêre doel was om te onderskei tussen kontaminasie in teaters waar nood en elektiewe chirurgie 
uitgevoer word en om te bepaal of daar ‘n verskil in propofol kontaminasie is tussen junior en meer 
senior narkose personeel.    
Ons het ‘n onaanvaarbare hoë prevalensie van propofol kontaminasie van 41.8% (95% CI: 32.5%, 
51.6%) gevind. Koagulase negatiewe stafilokokki was die mees prevalente organisme. Geen groei is 
gevind in 58.18% van die monsters na 2 dae. Wat betref ons sekondêre doel, was daar geen statisties 
beduidende verskil in die prevalensie van propofol kontaminasie in die monsters geneem in die nood en 
elektiewe teaters nie (p = 0.95; risk ratio 1.02; 95% CI: 0.55; 1.89). Daar was ook geen verskil in 
monsters van spuite gebruik deur junior en meer senior narkose personeel nie (p = 0.65; risk ratio 0.90; 
95% CI: 0.58; 1.41). 
Koagulase negatiewe stafilokokki is dikwels kontaminante en die meeste van die organismes wat ons 
gekweek het is nie patogenies in normale gashere nie. Dit kan egter dodelik wees in pasiënte wat 
imuunkompromiseerd is. Kontaminasie met kommensale organismes dien as a waarskuwing dat enige 
patogene (insluitend virusse) op die narkotiseur se hande of in die omgewing in die propofol mag land.  
Die teenwoordigheid van menslike kommensale organismes sowel as omgewings organismes in die 
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5. LITERATURE REVIEW 
Propofol, an intravenous anaesthetic agent, is commonly used for both in- and outpatient surgical 
procedures.1 
Propofol’s hypnotic effects result from its potentiation of the inhibitory function of the neurotransmitter 
gamma-aminobutyric acid (GABA). Quick onset of action and rapid elimination make it an ideal drug 
for monitored anaesthetic care in ambulatory surgery, sedation in intensive care units and for total 
intravenous anaesthesia (TIVA).2 -6  
Unfortunately, soon after introduction into clinical practice in 1989, various infections related to the 
intravenous use of propofol were reported and the lipophilic solution has since consistently been shown 
to support bacterial growth. ⁷ 
Biochemical data 
Propofol (2,6-diisopropylphenol) is dissolved in a hydrophobic emulsion manufactured as a 1% and a 
2% solution in a glass ampule. The emulsion consists of 10% soybean oil, 1.2% egg phospholipid and 
0.25% glycerine. The preparation is an isotonic solution and has a pH of 7 to 8.5, creating a favourable 
environment for bacterial growth.8 
Propofol uses 
At a dose of 2 to 2,5mg/kg, propofol reliably suppresses airway reflexes, producing optimal conditions 
for intubation or placement of a laryngeal mask.9,10 Propofol has antipruritic as well as anti-emetic 
properties and can aid in terminating seizures. Expert opinion is still divided regarding the analgesic or 
anti-hypersensitivity effects of propofol, given conflicting reports in experimental and clinical pain.11 
Propofol is a safe anesthetic agent in malignant hyperthermia suspectable patients.  
Pharmacodynamics 
Following intravenous administration, propofol often induces apnoea, depending on the dose, rate of 
administration and presence of other respiratory depressive drugs. Ventilatory response to CO2 and 
hypoxia is reduced. Propofol produces endothelium-independent vasodilatation, possibly through 
calcium channel antagonism. The cerebral metabolic rate is also lowered with resultant reduction in 





Loss of consciousness occurs in ‘one arm-brain circulation’ after an intravenous bolus, with effects 
lasting approximately 5 to 10 minutes. After prolonged infusion, the context-sensitive half-time is 
quoted as 40 minutes by the manufacturer.13 
Central nervous system (CNS) actions are primarily terminated by redistribution, due to the lipophilicity 
of the drug. Plasma elimination is mainly by hepatic metabolism (60%), with renal metabolism 
accounting for another 30% of extraction. Only 0.3% is secreted unchanged in the urine. 
Glucuronidation is the major metabolic pathway of propofol, with no active metabolites being 
produced.14  
Propofol as possible immunosuppressing agent  
Propofol is thought to impair the immune response of the host in various ways. Cytokines such as 
tumour necrosis factor alpha, which has pro-inflammatory properties, are reduced.15 
Inducible nitric oxide synthase (iNOS) gene expression is an important factor involved in antimicrobial 
barriers. Exposure to propofol reduces expression of iNOS and inhibits macrophage functioning.15-17  
Incidence and distribution of reports of propofol-related infections 
Twenty outbreaks of propofol related infections were reported from 1989 to 2014. In total, 144 patients 
were infected of whom 10 patients died.18 Vonberg and Gastmeier reported a mortality rate of 13.8% 
associated with propofol infections.18  
Geographically, the distribution of outbreaks was widespread in developed countries. No outbreaks have 
been reported in developing countries, most likely due to lack of follow-up. The incidence of 
contaminated propofol cases is greater in operating theatres than in the ICU with endoscopic procedures 
being the most frequently associated procedure.18 
Morbidity and mortality 
Introducing contaminated agents into the patient’s bloodstream can lead to systemic as well as surgical 
site infections. Length of hospital stay is increased by more than 7 days in patients with nosocomial 
bloodstream infections.19 
Bennett et al reported followed 49 patients who developed infections due to contaminated propofol 




them had a prolonged hospital stay, 11 patients underwent additional surgical procedures and 2 of the 
patients died.37 
Mechanisms of contamination of propofol formulations 
Microbiological contamination of propofol can occur during manufacturing (intrinsic) or from the 
environment after opening the ampule or vial (extrinsic). It has been well-documented that extrinsic 
methods of contamination are the most common, with only one report of a batch of intrinsically 
contaminated propofol in the USA in 2009.18 Extrinsic contamination may occur during storage and 
breakage of ampules or during drawing up into, and handling of syringes. Recent evidence suggest that 
unused syringes lying in operating theatres results in a contamination rate of 10%, which can increase to 
26.5% with recapping of syringes.19 Zacher et al. showed that swabbing the neck of propofol ampules 
with an alcohol swab prior to opening it, reduces bacterial contamination.20 Hemingway et al. 
investigated 100 ampules of fentanyl and diamorphine that had been wiped with isopropyl alcohol and 
were compared with  ampules that had not been wiped. Microorganisms were found on the inside neck 
of 18% of the ampules that had not been wiped and none on the wiped ampules.21  
The majority of reports of extrinsic contamination occurred in previously used vials, syringes or 
microdroppers as well as intravenous (IV) injection port dead spaces that served as reservoirs for 
bacterial growth.18 Environmentally exposed ampoules that are not used immediately have been 
identified as a contributing factor with an increase in contamination risk of 25% within 12 hours.18 It has 
been shown that re-using vials and pump infusion lines as well as preparing multiple propofol syringes 
in advance increase the risk for bacterial contamination.22, 23 
Price and Loftus described the transmission of various organisms from the surrounding environment, 
especially within the anaesthetic workstation.24, 25 The patient’s skin, frequently touched environmental 
sites around the patient, hands, gowns and gloves were all potential sources of pathogen spread. Despite 
having been proven to decrease spread of infection, adherence by operating theatre staff to hand-hygiene 
guidelines is significantly low and has been repeatedly shown to be the cause of bacterial contamination 
of propofol.26-29 Anaesthetists’ hands account for about 50% of contamination events.19 
Following the first propofol associated post-surgical fevers and infections, in 1990, the United States 
Food and Drug Administration (FDA) issued recommendations for strict aseptic drug handling 




• Propofol handling guidelines as recommended by the FDA: Vials and ampules of propofol and 
prefilled syringes are intended for single-patient use. 
• Strict aseptic technique must be practised when handling injectable medications. 
• Vials and ampules should be inspected before use for particulate matter, discoloration, or 
evidence of separation of the emulsion. Do not use if contaminated. 
• Fill syringes or spike the vial immediately before administration to each patient. Begin infusion 
immediately after drawing up or opening the vial/ampule. 
• Disinfect vial rubber stoppers with 70% isopropyl alcohol. 
• Discard unused portions within 6 hours of filling syringes or 12 hours after spiking a large 
volume vial/ampule for infusion. 
The South African Society of Anaesthesiologists (SASA) recently published similar guidelines for the 
prevention of anaesthetic related infections.30 Breedt et al. conducted an anonymous survey to determine 
whether SASA members are aware of existing guidelines, and if so, whether they adhere to aseptic 
handling techniques. They concluded that unsafe practices regarding handling and administration of 
propofol persisted and that the guidelines were of low impact.30 Of the 542 members that participated in 
the survey, 61% were aware of the guidelines, with 47.3% having read and familiarized themselves with 
the guidelines. The general practice of participants revealed that 16% admitted to using the same 
propofol syringe on various patients while 21% of the participants reused 50ml syringes for infusions 
and 30% of the latter group used the same extension tubing for different patients. The authors noted no 
reports of infection associated with propofol use occurring where safe injection practices were 
followed.30 
Seeberger et al. also studied the effect of educating staff and stringent implementation of correct aseptic 
handling of propofol. Practices were monitored by an infection control practitioner. They concluded that 
the aseptic precautions were efficient and with proper education, propofol-related infections could be 
prevented.31  
Microorganisms  
Numerous studies have shown propofol to provide an excellent growth medium for not only bacteria, 




survival of hepatitis C virus.36 Zorrilla-Vaca et al. reported that 23% of published infection outbreaks 
were due to hepatitis C with hepatitis B virus demonstrated in 4.2% 18 27.1% of infections were caused 
by Gram positive organisms and 20.1% by Gram negative organisms. Staphylococcus aureus remained 
the most common pathogen.18  
According to Bennett et al. most postoperative infections traced to contaminated propofol were caused 
by Staphylococcus aureus, Candida albicans, Moraxella osloensis, Enterobacter agglomerans and 
Serratia marcescens.37  
Other pathogens that have been grown from extrinsically contaminated propofol are the Gram negative 
organisms Klebsiella pneumoniae and Serratia marcescens.37 Cilli and Henry reported isolating S 
marcescens from propofol syringes, blood, and respiratory cultures, after patients developed wound 
sepsis or bacteremia post-surgery.38, 39 Endotoxin production has also been demonstrated.19 A recent 
study by Zorilla-Vaca grew Corynebacterium species, S. epidermidis, Bacillus species, Enterococcus 
faecalis, Micrococcus and Pseudomonas aeruginosa from contaminated propofol vials.40 Coagulase 
negative Staphylococci (CONS) other than S. epidermidis have been demonstrated as well.  
Improving propofol formulations 
Many proposed antimicrobial agents have been suggested to retard the growth of microorganisms should 
accidental contamination occur. Most investigated agents have been rejected due to poor efficacy, 
adverse side effects and high costs. The FDA requires that additives must retard microorganism growth 
to <10 fold at 24 hours after contamination. Adding ionically charged solutions to propofol can also 
destabilise the lipid emulsion, which prohibits the use of some additives. 
June 1996 brought about the addition of a preservative; disodium edetate (EDTA), a water-soluble 
chemical which retards microbial proliferation. It removes divalent and trivalent metal cations by 
chelation, leading to bursting of the microbial cell membrane. Although it does slow bacterial growth, it 
does not inhibit growth completely, and adhering to aseptic techniques are still emphasised. Propofol 
preparations containing EDTA are very expensive, further limiting use.18, 41-44  
Adding lidocaine to propofol also has antibacterial effects.45, 46 However, even when present in effective 
concentrations, it does not exert a sufficient retarding effect on microbial proliferation and poses the risk 




Fospropofol, a water-soluble prodrug of propofol, used mainly for sedation, has been shown to be a less 
favourable medium for bacterial growth. Transient paraesthesia and pruritus on injection are common 
side effects.48, 49 Benzyl alcohol has antimicrobial activity at low concentrations, but its use is limited by 
toxicity. Hall et al. demonstrated the efficacy of a 0.4 micron filter (EmulSivTM filter) which would serve 
as an additional precaution to prevent bacteria from entering the solution.50 The EmulSiv filter is a 
potentially viable solution to the problem of extrinsic contamination, if production costs can be lowered. 
Due to multiple concerns regarding bacterial contamination as well as pain on administration and 
hyperlipidaemia, propofol has undergone various transformations over the years in attempts to overcome 
these unwanted adverse effects. Focus has been geared towards the addition of external compounds. 
However, major safety concerns continue to require further research.51 Newer developments have not 




6. STUDY OBJECTIVE 
Breedt et al.30 has shown that general adherence to the manufacturer’s guidelines regarding propofol 
usage is low among anaesthetists in South Africa. The objective of this study was to investigate the 
prevalence of extrinsic contamination and resulting bacterial growth that occurs with use and possibly 
reuse of Fresenius Propoven 1% (10mg/ml, 20ml) (Fresenius Kabi, Sweden) in the Tygerberg Hospital 
operating theatres. 
Secondary objectives were formulated around modifiable aspects that could potentially influence results 
and shed light on target groups and areas for intervention. Hence the experience and seniority of the 
attending doctor was included. The assumption was also made that emergency theatres will yield a 
higher prevalence of contamination as opposed to the more organised and structured approach in theatres 





7.1 Research design 
We conducted an observational study to determine the prevalence of extrinsic propofol contamination in 
the Tygerberg Hospital operating theatres.  
After ethical approval was granted, we collected a total of 110 samples from propofol-containing 
syringes in randomly selected operating theatres, using a strictly aseptic technique. Specimens were 
obtained over a period of three weeks from the 25th of November 2019 and sent for laboratory analysis. 
We randomized the operating theatres by drawing the theatres to be sampled (A to Z) from a hat each 
day. We collected samples at different times of day between 07:00 and 15:30, in order to reduce 
performance bias. 
During the three-week study period, we took 17 samples from the four emergency theatres and 93 
samples from theatres dedicated to elective procedures. As the theaters from which specimens were 
taken were randomly chosen, the surgical disciplines as well as the seniority of the anaesthetists can be 
considered to be random. Senior anaesthetists in our study were defined as specialist anaesthetists and 
registrars who have completed intensive care and cardiothoracic rotations. Juniors included registrars in 
their first two years of the program as well as medical officers. Elective surgery included procedures 
performed by plastic, neuro, general, urology, paediatric, orthopaedic, gynaecological and cardiac 
surgical teams. In order to minimize the Hawthorne effect, theatre staff was not made aware of the study 
prior to sample collection. 
All specimens were collected by the author. By not directly involving patients in the study, we avoided 
multiple confounding factors and the possibility of infringing patient autonomy.  
7.2 Specimen collection 
We withdrew 1ml propofol specimens from any propofol syringe that has already been used for drug 
administration, using sterile gloves, a sterile 5ml syringe and an 18G needle. We injected the samples 
into culture bottles and sent them to the Tygerberg National Health Laboratory Service (NHLS) 
Microbiology laboratory for testing for growth of organisms. The bottled medium comprised a nutrient 




South Africa). The broth is a buffered beef extract containing Lab-Lemco powder, a specially selected 
meat extract and raw materials refined to a powder consistency.  
The laboratory protocol for incubation of the specimens each consisting of a 1ml sample of propofol in 
5ml BHI Broth (a one in six dilution) was as follows: 
• On receipt of the specimen, 100µl of the sample was plated onto a chocolate blood agar (CBA) 
plate. CBA was chosen as this grows the largest variety of aerobic organisms.  
• The CBA plate was incubated for 24 hours at 35°C in ambient air.  
• A colony count was done after incubation (Day one). 
Colony count formula: number of colonies on plate x 10 = number of colonies per ml x 6 (dilution 1:6 
above) = total colony count of original 1ml of propofol. 
• The original sample also incubated for 24hrs at 35°C in ambient air 
Day 1:  
• Sample was then plated onto a tryptose blood agar, CBA and McConkey agar. All plates were 
incubated for 24 hours at 35°C in ambient air. 
• Colony count done as above. 
Day 2: 
Growth was evaluated and identification of organisms done as follows: 
• Conventional biochemical tests 
• Automated identification on a Vitek®2 machine (bioMὲrieux, Marcy l’Etoile, France) machine - 
a microbial identification system. 
7.3 Data captured  
We entered the following information into an Excel® spreadsheet: 
• Most senior attending anaesthetist: Junior vs Senior Registrar  
• Emergency or elective theatre 




• Estimated time of opening of propofol ampule and time the sample was taken 
• Whether lignocaine had been added or not 
• Culture result and colony count 
No samples were taken from specimens where the above information could not reliably be attained. As 
such, none of our collected specimens were excluded from the study. 
7.4 Quality control 
We took care to ensure that specimens were collected correctly, using strict aseptic technique. 
Equipment, including swabs, syringes and gloves were standardized and all expiry dates checked prior to 
usage. Delivery to the laboratory was timeous and standard laboratory protocols were followed as per 
the National Health Laboratory Service. Entry of data in spreadsheet was also checked for accuracy.  
7.5 Strengths and limitations  
Multiple confounding factors and the possibility of infringing on patient autonomy has been avoided due 
to the laboratory nature of the study.  
It is the first study investigating propofol contamination done at our institution and the results will have 
a major impact on patient management. Clinicians will be more aware of their contribution towards 
postoperative infection and by them changing their practice, the incidence of morbidity and subsequent 
length of hospital stay may be significantly reduced. 
Limitations to this study include the fact that it is a single center study and cannot be extrapolated to 




8. DATA MANAGEMENT AND STATISTICAL ANALYSIS  
8.1 Determination of sample size 
Sample size estimation was done using openepi.com software.52 Based on an anticipated contamination 
prevalence of 6%, we established that a sample size of 100 specimens would enable us to detect the rate 
of contamination.   
8.2 Statistical methods 
We analysed the data using Stata version 15 (Statacorp, College Station, TX, USA). We employed 
Pearson’s Chi-square test of independence to assess the presence of any significant relationship between 
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10.1 Primary outcomes 
Forty-six of the 110 propofol samples produced bacterial cultures (41.8%; 95% CI:32.5%; 51.6%). Of 
these, 31% of the 110 samples produced cultures of coagulase negative staphylococcus organisms (e.g., 
Staphylococcus epidermidis, Staphylococcus haemolyticus). 
The remaining cultures consisted of mixed growths of environmental flora each comprising 2% of the 
sample. Bacillus species and Clostridium histolyticum comprised 2%. Table 10.1 lists the organisms that 
were cultured. 













Figure 10.2: Numbers of bacterial species cultured from 110 propofol-containing syringes.  
 
 





10.2 Secondary outcomes 
 
Figure 10.3: Comparison of proportions of contaminated propofol syringes obtained from  
  operating theatres in which senior versus junior anaesthetists were the attending  
  physicians 
 
 
(CNS: Coagulase negative Staphylococcus; BACSP: Bacillus species; CLOHI: Clostridium 
histolyticum; BACCE: Bacillus cereus; STRPA: Streptococcus parasanguinis; STAEP: Staphylococcus 





Figure 10.4: Comparison of proportions of contaminated propofol-containing syringes that  
  were obtained from elective versus emergency operating theatres   
 
(CNS: Coagulase negative Staphylococcus; BACSP: Bacillus species; CLOHI: Clostridium 
histolyticum; BACCE: Bacillus cereus; STRPA: Streptococcus parasanguinis; STAEP: Staphylococcus 















































In this study, 31% of organisms isolated were coagulase negative staphylococci (CONS), which include 
Staphylococcus epidermidis and Staphylococcus haemolyticus species. Staphylococcus epidermidis, a 
normal skin and mucous membrane colonizer, is benign in its interaction with its host and has not been 
reported to lead to severe infection or disease in immunocompetent individuals.53 Opportunistic 
infections do however occur and often involve indwelling medical devices and intravascular catheters, 
leading to bacterial sepsis.54 Staphylococcus haemolyticus is known to cause meningitis, soft tissue 
infections, prosthetic joint infections or blood stream infections.55 CONS’s inherent ability to cause a 
clinically manifested infection is determined by specie- and strain-specific virulence factors. One such 
factor is the ability to form biofilm, which promotes adherence and colonization of the organism on 
indwelling devices such as central venous catheters. CONS also contain genes for multiple drug 
resistance and is therefore complex to treat.56 Host specific defense mechanisms also affect susceptibility 
to infection.57 Sidhu et al. have demonstrated that the greater proportion (69.0%) of isolates of CONS 
were culture contaminants.58 They conducted a study to determine the rate of contamination of blood 
cultures in a tertiary hospital and isolated CONS from 307 of blood cultures. Only 74 out of the 307 
cases (24.1%) were pathogenic. In order to determine true pathogenicity, certain clinical and laboratory 




36˚C, hypotension (BP<90mmHg), neutropenia or disseminated intravascular coagulopathy. Laboratory 
criteria included: 2 sets of blood cultures yielding the same bacteria or isolating the same species in one 
set of initial blood samples and same duration for bacterial growth as a culture result from a different 
site. The clinical significance of these organisms is thus difficult to determine, considering the detection 
of CONS bactereamia has to be clinically correlated. Laboratory molecular identification as well as the 
number of colony-forming units (CFU) need to also be considered. The CFU/ml serves as a 
representation of the number of microorganisms in the sample that was plated.59, 60 The CFU ranged 
between no count up to 3060 CFU/ml. CONS yielded the highest CFU/ml (>4000CFU/ml). Bacillus 
species and CLOHI followed second highest with 2820CFU/ml. 
The correlation between the CFU and the number of bacteria present is not absolute as the addition of 
broth and solid media increases the complexity.  
Bacillus species, such as Bacillus cereus (2%), were among the cultured organisms. Their primary 
habitat is soil although they can be detected in water, decaying organic matter and in normal flora. It has 
been shown that most bacillus species have not been linked with major diseases in humans or animals, 
implying unimportant pathogenic activity although food poisoning and trauma induced infections 
involving bacillus species have been reported. Unfortunately, immunocompromised patients or the 
critically ill are at risk of falling victim to these opportunistic infections caused by bacilli. 61, 62 
Clostridium histolyticum were 1,8% of the contaminants. This species, a Gram-positive anaerobe, is 
found in soil and sometimes in faeces. It is can cause gas gangrene, releasing exotoxins resulting in 
necrosis and proteolysis. It has been found to play a role in ulcerative colitis and can also result in 
infective endocarditis among intravenous drug users.63  
Streptococcus parasanguinis formed 0.91%% of the contaminants. It is an atypical viridans Gram-
positive bacterial species, colonizes various body parts, most commonly the oral cavity, and is 
commonly associated with valvular endocarditis.64.65 
The micrococcus species are aerobic Gram-positive organisms and colonize the skin, mucosa and 
oropharyngeal space. Immunocompromised or neutropenic patients are vulnerable to clinically 
significant infections caused by micrococci. They have occasionally been identified as the infective 





Our investigation of propofol syringes in Tygerberg Hospital theatre complex, revealed a contamination 
prevalence of 41.84% (95% CI: 32.5%, 51.6%), with coagulase negative staphylococci being the most 
prevalent organism. This is higher than the expected prevalence of 3 – 6.3%, as reported in the 
literature.40 These studies were however conducted in developed countries, making comparison difficult. 
Organisms cultured in Tygerberg Hospital are similiar to previous studies done, with the exception of 
Staphylococcus aureus which was not found. This organism was a common finding in most of the 
previous studies done. 18, 37, 40    
The majority of studies have shown that CONS are often contaminants and may likely not cause a 
clinically significant infection in affected patients. Admittingly, the bulk of organisms we cultured are 
non-pathogenic in normal hosts but can be lethal in immunocompromised patients. A follow up study 
can be done to identify the specific individual organisms, and patients can be followed up to determine 
whether this high rate of contamination does cause clinically significant infections postoperatively.  
Importantly, contamination by commensals is certainly a warning that any pathogens (including viruses) 
that may be present on the anaesthetist’s hands or in the environment may also end up in the propofol.62, 
66    
No conclusion can be drawn from our secondary outcomes’ results, with wide confidence intervals. It is 
thus difficult to interpret whether the contamination rate is higher with more junior or more senior 
personnel. The majority of specimens were taken from elective theatres, and although we suspected 
emergency surgery and the associated urgency to influence aseptic handling of drugs, we cannot reliably 
indicate this. 
The prevalence of contamination in this study is still unacceptably high, considering that almost half of 
the syringes were contaminated. The presence of human commensals as well as environmental 
organisms in the propofol syringes are avoidable and zero contamination rate should be aspired to in all 
interactions with patients. Breedt et al. has reliably shown that there is awareness regarding the aseptic 
handling guidelines, and thus adherence to these recommendations seems to be the major problem30. 
With the aid of infection control, regular staff training should be implemented to create awareness and 
change behaviour. There should be easy and quick access to hand sanitizing agents in and around 




packaged with a small tag around the neck, emphasising aseptic handling techniques. While the use of 





12. CONCLUSION  
The severity of contamination of propofol in the Tygerberg Hospital operating theaters was 
demonstrated. Guidelines have been set in place to prevent complications caused by possible 
contaminants. Anaesthetists need to be made aware of their contribution to postoperative bacteraemias 
and wound infections in order to change their practice. Emphasis needs to be placed on regular hand 
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